Dr. Richard Aplenc, MD, PhD
Claim this profileChildren's Hospital of Philadelphia
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Myeloid Leukemia
6 reported clinical trials
16 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
CD33 positive
IDH positive
2Myeloid Leukemia
CD33 positive
IDH positive
Affiliated Hospitals
Clinical Trials Richard Aplenc, MD, PhD is currently running
CD123 Redirected T Cells
for Leukemia
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML).
Recruiting1 award Phase 16 criteria
Enasidenib
for Acute Myeloid Leukemia
This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractory). Patients must also have a specific genetic change, also called a mutation, in a protein called IDH2. Enasidenib may stop the growth of cancer cells by blocking the mutated IDH2 protein, which is needed for leukemia cell growth.
Recruiting1 award Phase 210 criteria
More about Richard Aplenc, MD, PhD
Clinical Trial Related9 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Richard Aplenc, MD, PhD has experience with
- CD33CART
- CART123 Cells
- Cyclophosphamide
- Fludarabine
- CPX-351
- Gilteritinib Fumarate
Breakdown of trials Richard Aplenc, MD, PhD has run
T-Lymphoblastic Leukemia/Lymphoma
Myeloid Leukemia
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Childhood Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Richard Aplenc, MD, PhD specialize in?
Richard Aplenc, MD, PhD focuses on T-Lymphoblastic Leukemia/Lymphoma and Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD33 positive patients, or patients who are IDH positive.
Is Richard Aplenc, MD, PhD currently recruiting for clinical trials?
Yes, Richard Aplenc, MD, PhD is currently recruiting for 3 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Richard Aplenc, MD, PhD has studied deeply?
Yes, Richard Aplenc, MD, PhD has studied treatments such as CD33CART, CART123 cells, Cyclophosphamide.
What is the best way to schedule an appointment with Richard Aplenc, MD, PhD?
Apply for one of the trials that Richard Aplenc, MD, PhD is conducting.
What is the office address of Richard Aplenc, MD, PhD?
The office of Richard Aplenc, MD, PhD is located at: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the Children's Hospital of Philadelphia.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.